In the past week, TNGX stock has gone down by -6.19%, with a monthly decline of -3.70% and a quarterly plunge of -38.04%. The volatility ratio for the week is 5.65%, and the volatility levels for the last 30 days are 5.50% for Tango Therapeutics Inc The simple moving average for the past 20 days is -3.09% for TNGX’s stock, with a -15.37% simple moving average for the past 200 days.
Is It Worth Investing in Tango Therapeutics Inc (NASDAQ: TNGX) Right Now?
The stock has a 36-month beta value of 0.84. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNGX is 54.88M, and at present, short sellers hold a 19.37% of that float. On May 02, 2024, the average trading volume of TNGX was 604.00K shares.
TNGX) stock’s latest price update
The stock price of Tango Therapeutics Inc (NASDAQ: TNGX) has dropped by -5.45 compared to previous close of 7.70. Despite this, the company has seen a fall of -6.19% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-18 that Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
Analysts’ Opinion of TNGX
Piper Sandler, on the other hand, stated in their research note that they expect to see TNGX reach a price target of $18. The rating they have provided for TNGX stocks is “Overweight” according to the report published on February 12th, 2024.
B. Riley Securities gave a rating of “Buy” to TNGX, setting the target price at $16 in the report published on December 08th of the previous year.
TNGX Trading at -18.11% from the 50-Day Moving Average
After a stumble in the market that brought TNGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.13% of loss for the given period.
Volatility was left at 5.50%, however, over the last 30 days, the volatility rate increased by 5.65%, as shares sank -5.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.94% lower at present.
During the last 5 trading sessions, TNGX fell by -6.19%, which changed the moving average for the period of 200-days by +105.07% in comparison to the 20-day moving average, which settled at $7.49. In addition, Tango Therapeutics Inc saw -26.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNGX starting from Third Rock Ventures IV, L.P., who sale 162,500 shares at the price of $12.00 back on Feb 20 ’24. After this action, Third Rock Ventures IV, L.P. now owns 19,201,475 shares of Tango Therapeutics Inc, valued at $1,950,000 using the latest closing price.
Weber Barbara, the Chief Executive Officer of Tango Therapeutics Inc, sale 4,457 shares at $12.62 during a trade that took place back on Feb 07 ’24, which means that Weber Barbara is holding 1,535,167 shares at $56,246 based on the most recent closing price.
Stock Fundamentals for TNGX
Current profitability levels for the company are sitting at:
- -3.13 for the present operating margin
- 0.89 for the gross margin
The net margin for Tango Therapeutics Inc stands at -2.72. The total capital return value is set at -0.32. Equity return is now at value -40.49, with -23.44 for asset returns.
Based on Tango Therapeutics Inc (TNGX), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.03. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is 196.51.
Currently, EBITDA for the company is -111.76 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 20.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.54.
Conclusion
To sum up, Tango Therapeutics Inc (TNGX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
